Paul Mann
Chief Executive Officer at ASP ISOTOPES INC.
Net worth: 24 M $ as of 30/03/2024
Profile
Mr. Paul E.
Mann, CFA, is a Chairman, Chief Executive Officer & Secretary at ASP Isotopes, Inc., a Chairman at Healthtech Solutions, Inc., a Chairman at Varian Biopharmaceuticals, Inc., a Chairman at Varian Biopharma, Inc. /New/ and a Chairman & Chief Executive Officer at Quantum Leap Energy LLC.
Mr. Mann was previously employed as an Independent Non-Executive Director by Abeona Therapeutics, Inc., a Chief Financial Officer by PolarityTE, Inc., an Analyst by SFM UK Management LLP, an Analyst by Althea Capital LLP, a Research Analyst by UBS AG (Private Banking UK), a Research Analyst by UBS Ltd.
(Broker), an Executive Director by Morgan Stanley & Co. LLC, an Analyst by Deutsche Bank AG (Broker UK), a Manager-Healthcare Portfolio by Highbridge Capital Management LLC, a Research Analyst by Morgan Stanley & Co. International Plc, a Research Scientist by Procter & Gamble Co., and an Analyst by Soros Fund Management LLC.
He received his graduate degree from the University of Cambridge.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ASP ISOTOPES, INC.
11.90% | 26/10/2023 | 5,805,643 ( 11.90% ) | 24 M $ | 30/03/2024 |
HEALTHTECH SOLUTIONS INC
2.77% | 27/06/2023 | 2,666,667 ( 2.77% ) | 400 000 $ | 29/06/2023 |
Paul Mann active positions
| Companies | Position | Start |
|---|---|---|
| HEALTHTECH SOLUTIONS INC. | Chairman | 20/09/2021 |
| ASP ISOTOPES INC. | Chief Executive Officer | 12/09/2021 |
Varian Biopharmaceuticals, Inc.
 Varian Biopharmaceuticals, Inc. BiotechnologyHealth Technology Part of Healthtech Solutions, Inc., Varian Biopharmaceuticals, Inc. is a private precision oncology company based in Naples, FL. Varian Bio is developing novel therapeutics for the treatment of cancer using precision oncology, which involves DNA testing to identify genetic mutations in tumors for more targeted treatment recommendations. Varian Bio's lead drug candidate, Var-101, is being developed in a topical formulation for the treatment of basal cell carcinoma, while Var-102, an oral formulation, is being developed for the treatment of various solid tumors, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Varian Bio is also seeking additional precision oncology therapeutic candidates for its pipeline and exploring development collaborations. The CEO of the company is Jeffrey Blaine Davis. Varian Biopharmaceuticals was acquired by Healthtech Solutions, Inc. on May 07, 2021. | Chairman | 31/05/2020 |
Former positions of Paul Mann
| Companies | Position | End |
|---|---|---|
| REGENETP, INC. | Director of Finance/CFO | 31/03/2020 |
SFM UK Management LLP
 SFM UK Management LLP Investment ManagersFinance SFM UK Management LLP (SFM UK) is the Great Britain-based alternative investment subsidiary of Soros Fund Management LLC in the US. Headquartered in London, SFM UK was founded in 2008 and manages assets of high net worth clients. | Analyst-Equity | 30/06/2014 |
| Althea Capital LLP | Analyst-Equity | 27/03/2013 |
UBS AG (Private Banking UK)
 UBS AG (Private Banking UK) Investment ManagersFinance UBS AG (Private Banking UK) is the Great Britain-based private banking division of UBS AG (London Branch), ultimately held by UBS Group AG (NYSE: UBS, SWX: UBSG) in Switzerland. Headquartered in London, the firm was founded 1998 and provides a range of private banking services to high-net worth clients. | Analyst-Equity | 08/03/2012 |
UBS Ltd. (Broker)
 UBS Ltd. (Broker) Investment Banks/BrokersFinance UBS Ltd. (Broker) is the Great Britain-based brokerage division of UBS Ltd.,the wholly-owned subsidiary of Switzerland-based UBS AG (SWX: UBSN; NYSE: UBS). Established in 1975, the firm is located in London. UBS Ltd.'s business is organized in three departments: fixed-income, rates and currencies; equity and investment banking. UBS Ltd. (Broker) engages in equity trading, equity derivatives and equity-linked products. The equity research department covers a diverse range of sectors globally and also supplies macroeconomic analysis, quantitative and derivative research. The fixed-income, rates and currency business covers credit, rates, commodities including energy and metals, municipal bonds, Forex and cash and collateral trading globally. Their investment banking activities include analysis, structuring, transaction negotiation and communication. | Analyst-Equity | 29/02/2012 |
Training of Paul Mann
| University of Cambridge | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
| ABEONA THERAPEUTICS INC. | Health Technology |
| REGENETP, INC. | Health Technology |
| ASP ISOTOPES INC. | Health Technology |
| Private companies | 11 |
|---|---|
Soros Fund Management LLC
 Soros Fund Management LLC Investment ManagersFinance Soros Fund Management LLC (SFM) is a privately-held investment management firm now structured as a family office, but which was once a hedge fund manager. The firm was founded in 1969 and is headquartered in New York City. SFM serves as principal investment adviser to a group of funds managed for the benefit of Soros family cl fsients. | Finance |
Highbridge Capital Management LLC
 Highbridge Capital Management LLC Investment ManagersFinance Highbridge Capital Management LLC (HCM Highbridge is a registered investment advisor and global alternative investment firm headquartered in New York City. The firm was founded in 1992 and is a subsidiary of JPMorgan Asset Management Holdings Inc., which is a wholly-owned subsidiary of JPMorgan Chase & Co. (NYSE: JPM). Highbridge manages capital for sophisticated investors, who include financial institutions, public and corporate pension funds, sovereign wealth funds, endowments and family offices. | Finance |
Morgan Stanley & Co. LLC
 Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry. | Finance |
UBS Ltd. (Broker)
UBS Ltd. (Broker) Investment Banks/BrokersFinance UBS Ltd. (Broker) is the Great Britain-based brokerage division of UBS Ltd.,the wholly-owned subsidiary of Switzerland-based UBS AG (SWX: UBSN; NYSE: UBS). Established in 1975, the firm is located in London. UBS Ltd.'s business is organized in three departments: fixed-income, rates and currencies; equity and investment banking. UBS Ltd. (Broker) engages in equity trading, equity derivatives and equity-linked products. The equity research department covers a diverse range of sectors globally and also supplies macroeconomic analysis, quantitative and derivative research. The fixed-income, rates and currency business covers credit, rates, commodities including energy and metals, municipal bonds, Forex and cash and collateral trading globally. Their investment banking activities include analysis, structuring, transaction negotiation and communication. | Finance |
Deutsche Bank AG (Broker UK)
 Deutsche Bank AG (Broker UK) Investment Banks/BrokersFinance Deutsche Bank AG (Deutsche Bank UK) is the UK-based securities brokerage division of Deutsche Bank AG (ETR: DBK) in Germany. The firm is headquartered in London and was founded in 1873. Deutsche Bank provides brokerage services to companies and institutions. | Finance |
Morgan Stanley & Co. International Plc
 Morgan Stanley & Co. International Plc Regional BanksFinance Morgan Stanley & Co. International Plc (MSCI) is a brokerage firm headquartered in London, UK. The firm was founded in 1986 and is a subsidiary of Morgan Stanley Investments (UK), ultimately held by Morgan Stanley (NYSE: MS) in the US. MSCI provides a range of brokerage services to corporations, governments and financial institutions. | Finance |
| Healthtech Solutions, Inc. | |
| Althea Capital LLP | Finance |
SFM UK Management LLP
SFM UK Management LLP Investment ManagersFinance SFM UK Management LLP (SFM UK) is the Great Britain-based alternative investment subsidiary of Soros Fund Management LLC in the US. Headquartered in London, SFM UK was founded in 2008 and manages assets of high net worth clients. | Finance |
UBS AG (Private Banking UK)
UBS AG (Private Banking UK) Investment ManagersFinance UBS AG (Private Banking UK) is the Great Britain-based private banking division of UBS AG (London Branch), ultimately held by UBS Group AG (NYSE: UBS, SWX: UBSG) in Switzerland. Headquartered in London, the firm was founded 1998 and provides a range of private banking services to high-net worth clients. | Finance |
Varian Biopharmaceuticals, Inc.
Varian Biopharmaceuticals, Inc. BiotechnologyHealth Technology Part of Healthtech Solutions, Inc., Varian Biopharmaceuticals, Inc. is a private precision oncology company based in Naples, FL. Varian Bio is developing novel therapeutics for the treatment of cancer using precision oncology, which involves DNA testing to identify genetic mutations in tumors for more targeted treatment recommendations. Varian Bio's lead drug candidate, Var-101, is being developed in a topical formulation for the treatment of basal cell carcinoma, while Var-102, an oral formulation, is being developed for the treatment of various solid tumors, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Varian Bio is also seeking additional precision oncology therapeutic candidates for its pipeline and exploring development collaborations. The CEO of the company is Jeffrey Blaine Davis. Varian Biopharmaceuticals was acquired by Healthtech Solutions, Inc. on May 07, 2021. | Health Technology |
- Stock Market
- Insiders
- Paul Mann
